{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T17:51:32Z","timestamp":1794851492113,"version":"4.9.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,11,6]],"date-time":"2020-11-06T00:00:00Z","timestamp":1604620800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,11,6]],"date-time":"2020-11-06T00:00:00Z","timestamp":1604620800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1007\/s00198-020-05699-0","type":"journal-article","created":{"date-parts":[[2020,11,6]],"date-time":"2020-11-06T14:02:41Z","timestamp":1604671361000},"page":"165-171","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Combining fracture outcomes in phase 3 trials of osteoporosis: an analysis of the effects of denosumab in postmenopausal women"],"prefix":"10.1007","volume":"32","author":[{"given":"J. A.","family":"Kanis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N. C.","family":"Harvey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Lorentzon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Vandenput","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. V.","family":"McCloskey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Johansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,6]]},"reference":[{"key":"5699_CR1","unstructured":"Committee for Medicinal Products for Human Use (CHMP) (2006) Guideline on the evaluation of medicinal products in the treatment of primary osteoporosis. Ref CPMP\/EWP\/552\/95Rev2 London, CHMP Nov 2006"},{"key":"5699_CR2","volume-title":"Guidelines for preclinical and clinical evaluation of agents used in the prevention or treatment of postmenopausal osteoporosis","author":"Food and Drug Administration","year":"1994","unstructured":"Food and Drug Administration (1994) Guidelines for preclinical and clinical evaluation of agents used in the prevention or treatment of postmenopausal osteoporosis. Division of Metabolism and Endocrine Drug Products, Rockville"},{"key":"5699_CR3","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1001\/jama.2009.50","volume":"301","author":"D Bliuc","year":"2009","unstructured":"Bliuc D, Nguyen ND, Milch VE, Nguyen TV, Eisman JA, Center JR (2009) Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. JAMA 301:513\u2013521","journal-title":"JAMA"},{"key":"5699_CR4","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/s001980200033","volume":"13","author":"SE Gabriel","year":"2002","unstructured":"Gabriel SE, Tosteson AN, Leibson CL, Crowson CS, Pond GR, Hammond CS, Melton LJ 3rd (2002) Direct medical costs attributable to osteoporotic fractures. Osteoporos Int 13:323\u2013330","journal-title":"Osteoporos Int"},{"key":"5699_CR5","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s00198-002-1316-9","volume":"14","author":"R Hasserius","year":"2003","unstructured":"Hasserius R, Karlsson MK, Nilsson BE, Redlund-Johnell I, Johnell O (2003) Prevalent vertebral deformities predict increased mortality and increased fracture rate in both men and women: a 10-year population-based study of 598 individuals from the Swedish cohort in the European Vertebral Osteoporosis Study. Osteoporos Int 14:61\u201368","journal-title":"Osteoporos Int"},{"key":"5699_CR6","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1359\/jbmr.2003.18.7.1254","volume":"18","author":"T Jalava","year":"2003","unstructured":"Jalava T, Sarna S, Pylkkanen L, Mawer B, Kanis JA, Selby P, Michael Davies M, Adams J, Francis RM, Robinson J, McCloskey E (2003) Association between vertebral fracture and increased mortality in osteoporotic patients. J Bone Miner Res 18:1254\u20131260","journal-title":"J Bone Miner Res"},{"key":"5699_CR7","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1007\/s00223-001-1045-7","volume":"69","author":"O Johnell","year":"2001","unstructured":"Johnell O, Kanis J, Gullberg G (2001) Mortality, morbidity, and assessment of fracture risk in male osteoporosis. Calcif Tissue Int 69:182\u2013184","journal-title":"Calcif Tissue Int"},{"key":"5699_CR8","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1007\/s00198-004-1627-0","volume":"15","author":"O Johnell","year":"2004","unstructured":"Johnell O, Kanis JA (2004) An estimate of the worldwide prevalence, mortality and disability associated with hip fracture. Osteoporos Int 15:897\u2013902","journal-title":"Osteoporos Int"},{"key":"5699_CR9","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1007\/s00198-006-0172-4","volume":"17","author":"O Johnell","year":"2006","unstructured":"Johnell O, Kanis JA (2006) An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 17:1726\u20131733","journal-title":"Osteoporos Int"},{"key":"5699_CR10","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/S8756-3282(03)00061-9","volume":"32","author":"JA Kanis","year":"2003","unstructured":"Kanis JA, Oden A, Johnell O, De Laet C, Jonsson B, Oglesby AK (2003) The components of excess mortality after hip fracture. Bone 32:468\u2013473","journal-title":"Bone"},{"key":"5699_CR11","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1007\/s00198-003-1516-y","volume":"15","author":"JA Kanis","year":"2004","unstructured":"Kanis JA, Oden A, Johnell O, De Laet C, Jonsson B (2004) Excess mortality after hospitalisation for vertebral fracture. Osteoporos Int 15:108\u2013112","journal-title":"Osteoporos Int"},{"key":"5699_CR12","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s001980170112","volume":"12","author":"JA Kanis","year":"2001","unstructured":"Kanis JA, Oden A, Johnell O, Jonsson B, de Laet C, Dawson A (2001) The burden of osteoporotic fractures: a method for setting intervention thresholds. Osteoporos Int 12:417\u2013427","journal-title":"Osteoporos Int"},{"key":"5699_CR13","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1007\/s00198-009-0844-y","volume":"20","author":"T Peasgood","year":"2009","unstructured":"Peasgood T, Herrmann K, Kanis JA, Brazier JE (2009) An updated systematic review of Health State Utility Values for osteoporosis related conditions. Osteoporos Int 20:853\u2013868","journal-title":"Osteoporos Int"},{"key":"5699_CR14","first-page":"1","volume-title":"The global burden of disease","author":"CJL Murray","year":"1996","unstructured":"Murray CJL (1996) Rethinking DALYs. In: Murray CJL, Lopez AD (eds) The global burden of disease. WHO, Geneva, pp 1\u201389"},{"key":"5699_CR15","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1016\/S0140-6736(12)61766-8","volume":"380","author":"SS Lim","year":"2012","unstructured":"Lim SS, Vos T, Flaxman AD, Danaei G, Shibuya K, Adair-Rohani H et al (2012) A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380:2224\u20132260 Erratum in: Lancet. 2013; 381:628","journal-title":"Lancet"},{"key":"5699_CR16","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1056\/NEJMoa0809493","volume":"361","author":"SR Cummings","year":"2009","unstructured":"Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C, FREEDOM trial (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756\u2013765","journal-title":"N Engl J Med"},{"key":"5699_CR17","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1002\/jbmr.1606","volume":"27","author":"EV McCloskey","year":"2012","unstructured":"McCloskey EV, Johansson H, Oden A, Austin M, Siris E, Wang A, Lewiecki EM, Lorenc R, Libanati C, Kanis JA (2012) Denosumab reduces the risk of osteoporotic fractures in postmenopausal women, particularly in those with moderate to high fracture risk as assessed with FRAX. J Bone Miner Res 27:1480\u20131486","journal-title":"J Bone Miner Res"},{"key":"5699_CR18","unstructured":"Oppe M, Devlin NJ, Szende A (2007) EQ-5D value sets: inventory, comparative review and user guide. Springer, EuroQol Group Monographs, Vol. 2"},{"issue":"8","key":"5699_CR19","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1302\/0301-620X.96B8.33766","volume":"96-B","author":"KL Haywood","year":"2014","unstructured":"Haywood KL, Griffin XL, Achten J, Costa ML (2014) Developing a core outcome set for hip fracture trials. Bone Joint J 96-B(8):1016\u20131023","journal-title":"Bone Joint J"},{"key":"5699_CR20","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1007\/s00198-017-4317-4","volume":"29","author":"A Svedbom","year":"2018","unstructured":"Svedbom A, Borgstr\u00f6m B, Hernlund E, Str\u00f6m O, Alekna V, Bianchi ML, Clark P, Curiel MD, Dimai HP, J\u00fcrisson M, Kallikorm R, Lember M, Lesnyak O, McCloskey E, Sanders KM, Silverman S, Solodovnikov A, Tamulaitiene M, Thomas T, Toroptsova N, Uusk\u00fcla A, Tosteson ANA, J\u00f6nsson B, Kanis JA (2018) Quality of life for up to 18 months after low-energy hip, vertebral, and distal forearm fractures-results from the ICUROS. Osteoporos Int 29:557\u2013566","journal-title":"Osteoporos Int"},{"key":"5699_CR21","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1007\/s00198-018-4502-0","volume":"29","author":"JA Kanis","year":"2018","unstructured":"Kanis JA, Johansson H, Od\u00e9n A, Harvey NC, Gudnason V, Sanders K, Sigurdsson G, Siggeirsdottir K, Borgstr\u00f6m F, McCloskey EV (2018) Characteristics of recurrent fractures. Osteoporos Int 29:1747\u20131757","journal-title":"Osteoporos Int"},{"key":"5699_CR22","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/s00198-003-1463-7","volume":"15","author":"JA Kanis","year":"2004","unstructured":"Kanis JA, Johnell O, Oden A, Borgstrom F, Zethraeus N, De Laet C et al (2004) The risk and burden of vertebral fractures in Sweden. Osteoporos Int 15:20\u201326","journal-title":"Osteoporos Int"},{"key":"5699_CR23","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1097\/00005650-199711000-00002","volume":"35","author":"P Dolan","year":"1997","unstructured":"Dolan P (1997) Modeling valuations for EuroQol health states. Med Care 35:1095\u20131108","journal-title":"Med Care"},{"key":"5699_CR24","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s001980200052","volume":"13","author":"JA Kanis","year":"2002","unstructured":"Kanis JA, Oden A, Johnell O, Caulin F, Bone H, Alexandre J-M, Abadie E, Lekkerkerker F (2002) Uncertain future of trials in osteoporosis. Osteoporos Int 13:443\u2013449","journal-title":"Osteoporos Int"},{"key":"5699_CR25","unstructured":"Foundation of the National Institutes of Health (2016) Q&a with Dennis Black, PhD, Principal Investigator of the FNIH Biomarkers Consortium\u2019s Bone Quality Project Foundation of the National Institutes of Health https:\/\/fnih.org\/news\/announcements\/qa-dennis-black-phd-principal-investigator-fnih-biomarkers-consortium%E2%80%99s-bone-quality-project. Accessed 26 April 2020"},{"key":"5699_CR26","unstructured":"Keil DP (2015) The need for surrogate endpoints for fracture. FDA workshop: osteoporosis drug development: moving forward. https:\/\/www.fda.gov\/downloads\/Drugs\/NewsEvents\/UCM472386.pdf. Accessed 27 April 2020"},{"key":"5699_CR27","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/S0002-9343(01)01124-X","volume":"112","author":"SR Cummings","year":"2002","unstructured":"Cummings SR, Karpf DB, Harris F, Genant HK, Ensrud K, LaCroix AZ, Black DM (2002) Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med 112:281\u2013289","journal-title":"Am J Med"},{"key":"5699_CR28","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1210\/jcem.87.4.8415","volume":"87","author":"MC Hochberg","year":"2002","unstructured":"Hochberg MC, Greenspan S, Wasnich RD, Miller P, Thompson DE, Ross PD (2002) Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab 87:1586\u20131592","journal-title":"J Clin Endocrinol Metab"},{"key":"5699_CR29","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1002\/jbmr.3641","volume":"34","author":"ML Bouxsein","year":"2019","unstructured":"Bouxsein ML, Eastell R, Lui LY, Wu LA, de Papp AE, Grauer A, Marin F, Cauley JA, Bauer DC, Black DM, FNIH Bone Quality Project (2019) Change in bone density and reduction in fracture risk: a meta-regression of published trials. J Bone Miner Res 34:632\u2013642","journal-title":"J Bone Miner Res"},{"issue":"8","key":"5699_CR30","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/S2213-8587(20)30159-5","volume":"8","author":"DM Black","year":"2020","unstructured":"Black DM, Bauer DC, Vittinghoff E, Lui LY, Grauer A, Marin F, Khosla S, de Papp A, Mitlak B, Cauley JA, McCulloch CE, Eastell R, Bouxsein ML, Foundation for the National Institutes of Health Bone Quality Project (2020) Treatment-related changes in bone mineral density as a surrogate biomarker for fracture risk reduction: meta-regression analyses of individual patient data from multiple randomised controlled trials. Lancet Diabetes Endocrinol 8(8):672\u2013682. https:\/\/doi.org\/10.1016\/S2213-8587(20)30159-5","journal-title":"Lancet Diabetes Endocrinol"},{"key":"5699_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00223-013-9724-8","volume":"93","author":"M Hiligsmann","year":"2013","unstructured":"Hiligsmann M, Kanis JA, Compston J, Cooper C, Flamion B, Bergmann P, Body JJ, Boonen S, Bruyere O, Devogelaer JY, Goemaere S, Kaufman JM, Rozenberg S, Reginster JY (2013) Health technology assessment in osteoporosis. Calcif Tissue Int 93:1\u201314","journal-title":"Calcif Tissue Int"},{"key":"5699_CR32","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/j.beem.2014.04.001","volume":"28","author":"JA Kanis","year":"2014","unstructured":"Kanis JA, Hiligsmann M (2014) The application of health technology assessment in osteoporosis. Best Pract Res Clin Endocrinol Metab 28:895\u2013910","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"5699_CR33","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1007\/s11657-013-0136-1","volume":"8","author":"E Hernlund","year":"2013","unstructured":"Hernlund E, Svedbom A, Iverg\u00e5rd M, Compston J, Cooper C, Stenmark J, McCloskey EV, J\u00f6nsson B, Kanis JA (2013) Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the international Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos 8:136. https:\/\/doi.org\/10.1007\/s11657-013-0136-1","journal-title":"Arch Osteoporos"},{"key":"5699_CR34","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s11657-011-0060-1","volume":"6","author":"O Str\u00f6m","year":"2011","unstructured":"Str\u00f6m O, Borgstr\u00f6m F, Kanis JA, Compston J, Cooper C, McCloskey EV, J\u00f6nsson B (2011) Osteoporosis; burden, health care provision and opportunities in the EU. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos 6:59\u2013155","journal-title":"Arch Osteoporos"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-020-05699-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00198-020-05699-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-020-05699-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,22]],"date-time":"2020-12-22T16:21:17Z","timestamp":1608654077000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00198-020-05699-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,6]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["5699"],"URL":"https:\/\/doi.org\/10.1007\/s00198-020-05699-0","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,6]]},"assertion":[{"value":"3 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"E Liu, L Vandenput and H Johansson have no competing interests to declare.N. Harvey has received consultancy, lecture fees and honoraria from Alliance for Better Bone Health, AMGEN, MSD, EliLilly, Servier, Shire, UCB,\u00a0Kyowa Kirin, Consilient Healthcare, Radius Health and Internis Pharma.EV McCloskey has received consultancy\/lecture fees\/grant funding\/honoraria from AgNovos, Amgen, AstraZeneca,Consilient Healthcare, Fresenius Kabi,\u00a0Gilead, GSK, Hologic, Internis, Lilly, Merck, Novartis, Pfizer, Radius Health, RedxOncology, Roche, SanofiAventis, Servier, Synexus, UCB, Viiv, Warner\u00a0Chilcott, I3 Innovus and Unilever.JA Kanis reports grants from Amgen, Eli Lilly and Radius Health; consulting fees from Theramex.M Lorentzon has received lecture fees from Amgen, Lilly, Meda, Renapharma, UCB Pharma, and consulting fees fromAmgen, Radius Health, UCB\u00a0Pharma, Renapharma and Consilient Health, all outside the presented work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}